Turnspire Capital Partners Completes Acquisition of Pharmachem Innovations from Ashland

September 3, 2024

Turnspire Capital Partners has acquired Pharmachem Innovations, the former nutraceuticals business of Ashland Inc., creating an independent nutraceuticals platform. Pharmachem — a provider of proprietary nutrition ingredients, custom formulation and contract manufacturing with ~500 employees across facilities in New Jersey, Utah and Tamaulipas, Mexico — will be led by Executive Chairman Maurice Murphy and Interim CEO Jeff Rogers as Turnspire pursues operational growth opportunities.

Buyers
Turnspire Capital Partners LLC
Targets
Pharmachem Innovations, LLC
Sellers
Ashland Inc.
Industry
Food & Beverage
Location
New Jersey, United States
Transaction Type
Buyout

Explore More

Related Acquisitions

Track M&A activity that matters to you

Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.